News

Strategy, appointments, major clinical, medical and regulatory advances, and partnerships …: you can find all the latest Ipsen Group news below.

Search a news
Filter by date
15 / 01 / 2018 -
Ipsen at ASCO GI 2018

100
20 / 12 / 2017 -
Ipsen’s partner Exelixis announces U.S. FDA approval of CABOMETYX® Tablets for previously untreated advanced renal cell carcinoma

Exelixis, today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC).

100
31 / 03 / 2016 -
Top Tweets 2015

000